Press release
JAK Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive JAK Inhibitor Pipeline Report to explore emerging therapies, key JAK Inhibitor Companies, and future JAK Inhibitor treatment landscapes @ JAK Inhibitor Pipeline Outlook Report [https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the JAK Inhibitor Pipeline Report
* In February 2025:- Karyopharm Therapeutics Inc.:- The main purpose of this study with corresponding optional expansion is to evaluate the efficacy of selinexor in JAKi-naive participants with myelofibrosis (MF) and moderate thrombocytopenia based on spleen volume reduction (SVR). Additional efficacy and safety parameters will also be assessed during the study.
* In January 2025:- Geron Corporation- The purpose of the study is to evaluate the overall survival of participants treated with imetelstat compared to best available therapy with intermediate-2 or high-risk Myelofibrosis (MF) who are relapsed/refractory (R/R) to Janus Kinase (JAK)-Inhibitor treatment.
* In January 2025:- Sanofi:- The purpose of this study is to measure the efficacy and safety of treatment with amlitelimab solution for subcutaneous (SC) injection compared with placebo in participants with moderate-to-severe AD aged 12 years and older on background TCS and have had an inadequate response to prior biologic or an oral JAKi therapy.
* In January 2025:- Celon Pharma SA;- The purpose of the following phase II clinical trial is to determine safety and effectiveness of Janus kinases and Rho-kinases inhibitor (JAK/ROCKi) in patients with Rheumatoid arthritis after oral administration of investigational medicinal product (IMP) called CPL409116. JAK inhibitors are a new class of small molecule drugs that modulate inflammatory pathways by blocking one or more JAK receptors.
* DelveInsight's JAK Inhibitor pipeline report depicts a robust space with 90+ active players working to develop 90+ pipeline therapies for JAK Inhibitor treatment.
* The leading JAK Inhibitor Companies such as Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.
* Promising JAK Inhibitor Therapies such as Baricitinib, Busulfan, Cyclophosphamide, Ruxolitinib, Selinexor 60 mg, Ruxolitinib, Ritlecitinib, and others
Discover how the JAK Inhibitor treatment paradigm is evolving. Access DelveInsight's in-depth JAK Inhibitor Pipeline Analysis for a closer look at promising breakthroughs @ JAK Inhibitor Clinical Trials and Studies [https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
JAK Inhibitor Emerging Drugs Profile
* Povorcitinib: Incyte Corporation
Povorcitinib (INCB054707) is an oral small-molecule JAK1 inhibitor. The chemical structure for povorcitinib was revealed in WHO proposed INN list 126 (Jan 2022), in which it was described as a Janus kinase inhibitor and anti-inflammatory agent. The drug is also being evaluated in Phase II clinical trials for Prurigo Nodularis, and others. Currently, the drug is in Phase III stage of its development for the treatment of Hidradenitis suppurativa, vitiligo.
* CPL409116: Celon Pharma
CPL 409116 is the first in class dual JAK/ROCK inhibitor in clinical development and is designed to generate anti-inflammatory and anti-fibrotic effects in selected autoimmune diseases. CPL'116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial met its primary endpoint. Currently the drug is in Phase II stage of development for autoimmune indications including in patients with rheumatoid arthritis with coexisting interstitial lung disease.
* ATI-2138: Aclaris Therapeutics
ATI-2138 is an investigational oral covalent ITK/JAK3 inhibitor that is being developed as a potential therapeutic option across a variety of T cell-mediated diseases. ITK is a T cell receptor activated kinase involved in driving T cell effector functions while JAK3 is a non-receptor tyrosine kinase responsible for the signal transduction of common gamma receptor cytokines, IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21. In blocking both T cell receptor function and cytokine signaling, ATI-2138 has potential utility in T cell driven diseases. ATI-2138 is currently in clinical development and its safety and efficacy has not been evaluated by regulatory authorities.
* SDC 1802: Sareum
SDC-1802 is an investigational Sareum's TYK2/JAK1 preclinical development candidate molecule that demonstrates high selectivity for TYK2 and JAK1 kinases (particularly over related JAK2 and JAK3). SDC-1802 shows compelling efficacy in blocking cancer cell proliferation in cellular and disease models of T-cell acute lymphoblastic leukaemia (T-ALL) and B-cell lymphoma, the potential for once-daily oral dosing and a good early safety profile. Sareum is progressing SDC-1802 through preclinical development and pending satisfactory progress, into human clinical trials. SDC-1802 has the potential to act as a back-up molecule for these autoimmune indications. Currently, the drug is in Preclinical stage of its development for the treatment of cancer.
Get a detailed analysis of the latest innovations in the JAK Inhibitor pipeline. Explore DelveInsight's expert-driven report today! @ JAK Inhibitor Unmet Needs [https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
JAK Inhibitor Companies
Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.
JAK Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
JAK Inhibitor Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming JAK Inhibitor Therapies and key JAK Inhibitor Developments @ JAK Inhibitor Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the JAK Inhibitor Pipeline Report
* Coverage- Global
* JAK Inhibitor Companies- Incyte Corporation, Celon Pharma, Aclaris Therapeutics, Sareum, Takeda, AstraZeneca, Ajax Therapeutics, Pfizer, GSK, Dizal Pharmaceutical, Confluence Life Sciences, Arcutis Biotherapeutics/Reistone Biopharma and others.
* Promising JAK Inhibitor Therapies - Baricitinib, Busulfan, Cyclophosphamide, Ruxolitinib, Selinexor 60 mg, Ruxolitinib, Ritlecitinib, and others
* JAK Inhibitor Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* JAK Inhibitor Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in JAK Inhibitor drug development? Find out in DelveInsight's exclusive JAK Inhibitor Pipeline Report-access it now! @ JAK Inhibitor Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/janus-kinase-jak-inhibitor-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Janus Kinase (JAK) Inhibitor: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Janus Kinase (JAK) Inhibitor- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Povorcitinib: Incyte Corporation
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* CPL409116: Celon Pharma
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ATI-2138: Aclaris Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* SDC 1802: Sareum
* Drug profiles in the detailed report.....
* Inactive Products
* Janus Kinase (JAK) Inhibitor Key Companies
* Janus Kinase (JAK) Inhibitor Key Products
* Janus Kinase (JAK) Inhibitor- Unmet Needs
* Janus Kinase (JAK) Inhibitor- Market Drivers and Barriers
* Janus Kinase (JAK) Inhibitor- Future Perspectives and Conclusion
* Janus Kinase (JAK) Inhibitor Analyst Views
* Janus Kinase (JAK) Inhibitor Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=jak-inhibitor-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-and-companies-by-delveinsight]
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/urothelial-carcinoma-market
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release JAK Inhibitor Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight here
News-ID: 3860727 • Views: …
More Releases from ABNewswire
Central New York Revocable Trust Lawyers at Davies Law Firm Explain How Living T …
SYRACUSE, NY - Families across Central New York looking to secure their assets and provide clear instructions for future care are increasingly turning to living trusts as a practical solution. Frederick P. Davies and William P. Davies, Central New York Revocable Trust Lawyers at Davies Law Firm (https://davieslawfirm.com/how-a-living-trust-protects-your-family-in-new-york/), emphasize that a properly structured revocable living trust offers control, continuity, and privacy, three critical elements in planning for both incapacity and…
Houston Guardianship Attorney Whitney L. Thompson Clarifies Who Can Serve as a G …
Houston, Texas - Whitney L. Thompson, a Houston guardianship attorney and principal of The Law Office of Whitney L. Thompson (https://www.wthompsonlaw.com/who-can-serve-as-a-guardian-in-texas/), is providing clear guidance to families on who may serve as a court-appointed guardian under Texas law. The overview explains eligibility, disqualifying factors, and practical considerations for selecting a guardian, with the goal of promoting the least restrictive, most protective arrangements for vulnerable adults and minors.
Texas courts appoint guardians…
Traumatic Brain Injury Market Dynamics Indicate Upward Trajectory Through 2034, …
The Key Traumatic Brain Injury Companies in the market include - SanBio, Oxeia Biopharmaceuticals, Oragenics, Hope Biosciences, SHINKEI Therapeutics, VeriNOS Pharmaceuticals GmbH, Cellvation, Inc., Abalonex, LLC, The SanBio Group, Hope Biosciences, CereMark Pharma, LLC, Hamad Medical Corporation, Supernus Pharmaceuticals, Inc., Merz Pharmaceuticals GmbH, and others.
DelveInsight's "Traumatic Brain Injury Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Traumatic Brain Injury, historical and forecasted epidemiology as well…
Mobilo Named the #1 NFC Business Card Solution for Professionals and Modern Team …
Platform trusted by 59,732 businesses across 200+ countries delivers complete automation, enterprise-grade CRM integration, and intelligent lead scoring that transforms networking into measurable pipeline. Mobilo is thrilled to announce its recognition as the #1 NFC business card solution in the market, establishing itself as the premier platform for professionals and teams.
NEW YORK, NY - December 12, 2025 - Mobilo is thrilled to announce its recognition as the #1 NFC business…
More Releases for JAK
Key Trends Influencing the Growth of the Janus Kinase (JAK) Inhibitors Market in …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Janus Kinase (JAK) Inhibitors Market Through 2025?
The market size of Janus Kinase (JAK) inhibitors has experienced a quick growth over the recent years. The market, which stood at $20.19 billion in 2024, is projected to see a rise to $23.56 billion…
Global Jak And Pi3k Signaling Pathway Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Jak And Pi3k Signaling Pathway market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period.
The JAK and PI3K signaling pathway market is experiencing significant growth due to the increasing…
Leading Growth Driver in the Janus Kinase (JAK) Inhibitors Market in 2025: Surgi …
Which drivers are expected to have the greatest impact on the over the janus kinase (jak) inhibitors market's growth?
The escalating occurrences of autoimmune disorders are anticipated to stimulate the expansion of the Janus kinase (JAK) inhibitors market. These disorders involve a broad spectrum of abnormalities within the immune system where it erroneously attacks and destroys healthy cells, tissues, and organs. The therapeutic benefits of Janus Kinase (JAK) inhibitors for autoimmune…
Janus Kinase (JAK) Inhibitor Pipeline Therapeutics Assessment Report 2024 (Updat …
DelveInsight's, "Janus Kinase Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Janus Kinase (JAK) Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Janus Kinase…
Janus kinase (JAK) Inhibitors Competitive Landscape Report 2024
DelveInsight's, "Janus kinase inhibitors Competitive landscape 2024" report provides comprehensive insights about 40+ Janus kinase Inhibitors Companies and 45+ drugs in Janus kinase inhibitors Competitive landscape. It covers the Janus kinase Inhibitors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Janus kinase Inhibitors Report
• DelveInsight's Janus kinase Inhibitors report depicts a robust space…
Janus Kinase (JAK) Inhibitors Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Janus Kinase (JAK) Inhibitors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Janus Kinase (JAK) Inhibitors players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Janus Kinase (JAK)…
